MedTrace Logo

Topical Immuonosuppressant Drugs in Spring Catarrh

NCT04705584 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-01-12

No results posted yet for this study

Summary

Spring catarrh is a prevalent type of conjunctival allergic disorder in temperate countries. Topical steroids are the cornerstone management of spring catarrh beside other anti allergic drugs. However, prolonged use of topical steroids especqially in resistant spring catarrh carries risk of ocular side effects as 2nd glaucoma and cataract. We will investigate the safety and efficacy of topical immuonosuppressant in the management of resistant spring catarrh as an alternative to steroid therapy.

Conditions

  • Vernal Keratoconjunctivitis

Interventions

DRUG

Prednisolone (as Acetate)

Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.

DRUG

CycloSPORINE Ophthalmic Suspension

This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.

DRUG

LTacrolimus Topical

This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2021-10-31
Completion
2022-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705584 on ClinicalTrials.gov